IMMUCELL CORP /DE/ (ICCC)
$0.00+$0.00 (+0.00%) TodayExtended Hours
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 8,000 | $76K |
19 Form 4 filings on record, the earliest from Nov 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Boekhorst Paul Francis Olivier Te - Officer | Open-market purchase | Common Stock, par value $.01 per share | 8,000 | $9.50 | $76K | |
| Kathy V. Turner - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 17,899 | $0.00 | - | |
| David Scott Tomsche - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 11,933 | $0.00 | - | |
| Gloria F. Basse - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 11,933 | $0.00 | - | |
 Paul R. Wainman - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 11,933 | $0.00 | - | |
 Bryan K. Gathagan - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 10,000 | $0.00 | - | |
| Paul R. Wainman - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 10,000 | $0.00 | - | |
| David Scott Tomsche - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 10,000 | $0.00 | - | |
| Bobbi Jo Brockmann - Officer | Grant or award | Incentive Stock Options (Right to buy) | 5,000 | $0.00 | - | |
 Steven T. Rosgen - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 10,000 | $0.00 | - | |
| Gloria F. Basse - Director | Grant or award | Non Qualified Stock Options (Right to buy) | 10,000 | $0.00 | - | |
| Michael F. Brigham - Director | Option exercise | Stock Options (right to buy) | 25,000 | $0.00 | - | |
| Michael F. Brigham - Director | Option exercise | Common Stock, par value $.01 per share | 25,000 | $5.84 | $146K | |
| Michael F. Brigham - Director | Tax withholding / forfeiture | Common Stock, par value $.01 per share | 24,052 | $6.07 | $146K | |
| Boekhorst Paul Francis Olivier Te - Officer | Grant or award | Stock Options (right to buy) | 109,500 | $0.00 | - | |
| Timothy C. Fiori - Officer | Grant or award | Stock Options (right to buy) | 120,000 | $0.00 | - | |
| Bobbi Jo Brockmann - Officer | Grant or award | Stock Options (right to buy) | 100,000 | $0.00 | - | |
| Boekhorst Paul Francis Olivier Te - Officer | Grant or award | Stock Options (right to buy) | 110,000 | $0.00 | - | |
| Boekhorst Paul Francis Olivier Te - Officer | Open-market purchase | Common Stock $0.10 par value per share | 3,708 | $4.87 | $18K | |
| Boekhorst Paul Francis Olivier Te - Officer | Open-market purchase | Common Stock $0.10 par value per share | 2,556 | $5.00 | $13K | |
| Boekhorst Paul Francis Olivier Te - Officer | Open-market purchase | Common Stock $0.10 par value per share | 3,521 | $5.04 | $18K | |
| David Scott Tomsche - Director | Open-market purchase | Common Stock $0.10 par value per share | 1,633 | $4.76 | $8K | |
| David Scott Tomsche - Director | Open-market purchase | Common Stock $0.10 par value per share | 1,633 | $4.77 | $8K | |
| Boekhorst Paul Francis Olivier Te - Officer | Grant or award | Stock Options (right to buy) | 74,277 | $6.10 | $453K |
IMMUCELL CORP /DE/ (ICCC) had 1 insider filing in the last 90 days, with the most recent on 2026-06-22. The full record for ICCC runs to 19 Form 4 filings, the earliest from 2025-11-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of ICCC was filed in the last 90 days, totaling $76K.
No insider sales of ICCC were filed in the last 90 days.
This page tracks ICCC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ICCC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
